COMP <GO>
MYGN vs ICCC // ALTMAN Z-SCORE & DEBT/EQUITY
Myriad Genetics Inc. (NASDAQ) VS. ImmuCell Corporation (NASDAQ) • 15-METRIC TALLY: MYGN 3
— ICCC 7
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: ICCC
LAST: $6.67 (+0.60%) • MKT CAP: $638.0M
balance-sheet
0.20
LAST: $10.32 (-2.82%) • MKT CAP: $93.7M
balance-sheet
4.28
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MYGN VS. ICCC)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MYGN | ICCC | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 69.90% | 41.40% | +28.50 | MYGN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 4.20% | -39.20 | ICCC | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 35.9x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.28% | 1.31% | -1.03 | ICCC | /fcf-yield <GO> |
| Operating Margin | -47.00% | 6.00% | -53.00 | ICCC | /operating-margins <GO> |
| Net Profit Margin | -44.40% | -3.80% | -40.60 | ICCC | /net-margins <GO> |
| Revenue Growth (YoY) | -1.60% | 4.30% | -5.90 | ICCC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 0.20 | 4.28 | -4.08 | ICCC | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | ICCC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 72.7 | 50.5 | +22.17 | MYGN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $638.0M | $93.7M | $544.3M | MYGN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MYGN REV | ICCC REV | MYGN GROSS % | ICCC GROSS % | MYGN FCF | ICCC FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $824.5M | $27.6M | 69.9% | 41.4% | $1.8M | $1.2M |
| FY 2024 | $837.6M | $26.5M | 69.9% | 30.0% | -$8.7M | -$107.8K |
| FY 2023 | $753.2M | $17.5M | — | — | -$110.9M | -$4.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MYGN // BETA —
ICCC // BETA —